Skip to content

Study · In vitro (cells) · pseudomonas aeruginosa · 2018

5 results

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.

Sader HS, Dale GE, Rhomberg PR, Flamm RK

Antimicrobial agents and chemotherapy26 Jun 2018Cited by 46 (Europe PMC)

PMID29686157 (opens in a new tab)PMCIDPMC6021639 (opens in a new tab)DOI10.1128/aac.00311-18 (opens in a new tab)PepBankPUB-29686157
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In clinical isolates, murepavadin MIC50 and MIC90 were both 0.12 mg/liter.

    In plain wordsIn lab tests, murepavadin MIC50 and MIC90 were both 0.12 mg/liter.

    Peptide
    Murepavadin
    Outcome
    Not applicableMIC50 and MIC90
    Study

    Pseudomonas aeruginosan = 1,219

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    MIC50
    0.12 mg/liter
    Not specified
    MIC90
    0.12 mg/liter
    Not specified

    Source sentences

    Summary
    Murepavadin (MIC50/90, 0.12/0.12 mg/liter) was 4- to 8-fold more active than colistin (MIC50/90, 1/1 mg/liter) and polymyxin B (MIC50/90, 0.5/1 mg/liter) and inhibited 99.1% of isolates at ≤0.5 mg/liter.
    1 context sentence
    Summary · context
    Murepavadin (formerly POL7080), a 14-amino-acid cyclic peptide, and comparators were tested by the broth microdilution method against 1,219 Pseudomonas aeruginosa isolates from 112 medical centers.
  2. 02LabIn vitro (cells)Activity measurement

    In clinical isolates, murepavadin was 4- to 8-fold more active than colistin and polymyxin B.

    In plain wordsIn lab tests, murepavadin was 4- to 8-fold more active than colistin and polymyxin B.

    Peptide
    Murepavadin
    Outcome
    IncreaseActivity versus colistin and polymyxin B
    Study

    Pseudomonas aeruginosan = 1,219

    Clinical isolates
    Comparator
    Colistin and polymyxin B
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Murepavadin (MIC50/90, 0.12/0.12 mg/liter) was 4- to 8-fold more active than colistin (MIC50/90, 1/1 mg/liter) and polymyxin B (MIC50/90, 0.5/1 mg/liter) and inhibited 99.1% of isolates at ≤0.5 mg/liter.
    1 context sentence
    Summary · context
    Murepavadin (formerly POL7080), a 14-amino-acid cyclic peptide, and comparators were tested by the broth microdilution method against 1,219 Pseudomonas aeruginosa isolates from 112 medical centers.
  3. 03LabIn vitro (cells)Activity measurement

    In clinical isolates, murepavadin inhibited 99.1% at concentrations of ≤0.5 mg/liter.

    In plain wordsIn lab tests, murepavadin inhibited 99.1% of isolates at ≤0.5 mg/liter.

    Peptide
    Murepavadin
    Outcome
    Not applicableIsolate inhibition
    Study

    Pseudomonas aeruginosan = 1,219

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    Isolates inhibited
    99.1%
    ≤0.5 mg/liter

    Source sentences

    Summary
    Murepavadin (MIC50/90, 0.12/0.12 mg/liter) was 4- to 8-fold more active than colistin (MIC50/90, 1/1 mg/liter) and polymyxin B (MIC50/90, 0.5/1 mg/liter) and inhibited 99.1% of isolates at ≤0.5 mg/liter.
    1 context sentence
    Summary · context
    Murepavadin (formerly POL7080), a 14-amino-acid cyclic peptide, and comparators were tested by the broth microdilution method against 1,219 Pseudomonas aeruginosa isolates from 112 medical centers.
  4. 04LabIn vitro (cells)Activity measurement

    In clinical isolates, 4 isolates (0.3%) had murepavadin MICs above 2 mg/liter.

    In plain wordsIn lab tests, 4 isolates (0.3%) had murepavadin MICs above 2 mg/liter.

    Peptide
    Murepavadin
    Outcome
    Not applicableElevated MIC frequency
    Study

    Pseudomonas aeruginosan = 1,219

    Clinical isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    Elevated MIC isolates
    4 isolates
    >2 mg/liter
    Elevated MIC frequency
    0.3%
    >2 mg/liter

    Source sentences

    Summary
    Only 4 isolates (0.3%) exhibited murepavadin MICs of >2 mg/liter.
    1 context sentence
    Summary · context
    Murepavadin (formerly POL7080), a 14-amino-acid cyclic peptide, and comparators were tested by the broth microdilution method against 1,219 Pseudomonas aeruginosa isolates from 112 medical centers.
  5. 05LabIn vitro (cells)Activity measurement

    In clinical isolates, murepavadin was equally active across Europe, the United States and China.

    In plain wordsIn lab tests, murepavadin activity was equal across isolates from Europe, the United States and China.

    Peptide
    Murepavadin
    Outcome
    No significant changeActivity by geographic origin
    Study

    Pseudomonas aeruginosan: not reported in source

    Clinical isolates
    Comparator
    Isolates from Europe, United States and China
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Murepavadin was equally active against isolates from Europe, the United States, and China.
    1 context sentence
    Summary · context
    Murepavadin (formerly POL7080), a 14-amino-acid cyclic peptide, and comparators were tested by the broth microdilution method against 1,219 Pseudomonas aeruginosa isolates from 112 medical centers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.